A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
The outcome of patients with refractory leukemia and myelodysplasia is poor, and new therapies are needed. The antiapoptotic proteins of the Bcl-2 family are overexpressed in these malignancies and are potential therapeutic targets. Therefore, we conducted a phase I clinical trial of the small-molec...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2008
|
| Rochtain ar líne: | https://doi.org/10.1158/1078-0432.ccr-08-0999 https://clincancerres.aacrjournals.org/content/clincanres/14/24/8295.full.pdf |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|